Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04514016 · ClinicalTrials.gov registry record
Cross Sectional CFAR HIV/COVID-19 Study
A clinical trial, sponsored by University of Miami.
- Completed
- Registry status
- 64
- Enrollment target
NCT04514016: Completed study, sponsored by University of Miami.
NCT04514016 is a clinical trial that has completed, run by University of Miami. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04514016 has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
The main purpose of this research study is to learn the rate of SARS COV-2 on HIV infected children, adolescents, and youth receiving their primary HIV care at the University of Miami Miller School of Medicine.
Primary Outcome
SARS COV-2 Infection will be analyzed from nasopharyngeal swab samples via RT-PCR assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2021-03-17 |
What the finished NCT04514016 record still lists
NCT04514016 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 64 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04514016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04514016 about?
NCT04514016 is a clinical study titled "Cross Sectional CFAR HIV/COVID-19 Study". The main purpose of this research study is to learn the rate of SARS COV-2 on HIV infected children, adolescents, and youth receiving their primary HIV care at the University of Miami Miller School of Medicine.
What is the current status of trial NCT04514016?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2020-08-12. Estimated completion is 2021-03-17.
Who is sponsoring clinical trial NCT04514016?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI